Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron (Nasdaq: GERN) granted stock options to five new employees on May 15, 2026, as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options cover an aggregate 333,750 shares at an exercise price of $1.29 per share, with a ten-year term and four-year vesting.
Geron (Nasdaq: GERN) announced the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), to be presented at EHA 2026. The Moffitt Cancer Center study in 40 heavily pretreated, transfusion-dependent patients showed 37.5% achieving ≥8-week RBC transfusion independence and a safety profile consistent with prior data.
Geron will also present updated myelofibrosis overall survival analyses and early-phase acute myeloid leukemia and myelofibrosis combination trial data at EHA 2026 and ASCO 2026.
Geron (Nasdaq: GERN) reported Q1 2026 results with RYTELO net product revenue of $51.8M and a reduced net loss of $3.6M ($0.01/share). Cash and marketable securities were $341.0M at March 31, 2026. 2026 guidance reiterated: RYTELO revenue $220M–$240M and total operating expenses $230M–$240M. Key commercial and clinical progress includes demand growth, NCCN chemotherapy order template inclusion, ongoing IMpactMF Phase 3, and leadership additions.
Geron (Nasdaq: GERN) announced management presentations at investor conferences in May 2026. Presentations: Bank of America Healthcare Conference on May 12 at 4:35 p.m. ET in Las Vegas and a Stifel Virtual Targeted Oncology Forum presentation on May 20 at 12:00 p.m. ET. A live and archived audio webcast will be available via the company's Investors and Media website.
Geron (Nasdaq: GERN) will release its first quarter 2026 financial results and business highlights before the market opens on May 6, 2026.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time, with live and archived audio available from the Investors and Media section of its website at www.geron.com.
Geron Corporation (Nasdaq: GERN) reported inducement stock option grants effective April 17, 2026, totaling 855,000 shares to nine newly hired employees.
The options carry a $1.68 exercise price (closing price on the grant date), a 10-year term, and vest over four years with a 12.5% six-month cliff.
Geron (Nasdaq: GERN) granted a 2,500,000-share stock option to Timothy Williams as an inducement for joining as Executive Vice President, Chief Legal Officer and Corporate Secretary.
The option was granted April 13, 2026, has a $1.73 exercise price (equal to the grant-date close), a 10-year term and vests over four years with 12.5% vesting at six months.
Geron (Nasdaq: GERN) announced on April 13, 2026 the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams joins Geron after serving as Senior Vice President, General Counsel and Secretary at Vanda Pharmaceuticals from 2018 until March 2026.
Geron said Williams brings deep biopharma legal experience across commercial-stage companies, M&A, corporate governance, securities and compliance, and will support Geron’s strategy in hematology.
Geron (Nasdaq: GERN) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:00 a.m. ET. A live audio webcast and archived audio will be available via the Investors & Media section at geron.com.
Geron (Nasdaq: GERN) appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors on March 26, 2026.
Both appointees bring decades of biopharmaceutical leadership and commercial-stage experience and will support Geron's commercial strategy to drive growth for RYTELO.